Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX390 + Toripalimab in Advanced Solid Tumors
NCT06117566Phase 2Recruiting
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WXFL10030390 in solid tumor (3 arms), sponsored by Shanghai Jiatan Pharmatech. Primary endpoints: Maximum tolerated dose and dose-limiting toxicity up to 24 weeks, Progression-free survival rate up to 24 weeks and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
WXFL10030390
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06117566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117566.